Karyopharm Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 19, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: February 19, 2025 | KARYOPHARM THERAPEUTICS INC. | |
|---|---|---|
| By: | /s/ Richard Paulson | |
| Richard PaulsonPresident and Chief Executive Officer and Director(Principal Executive Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Richard Paulson | President and Chief Executive Officer and Director | February 19, 2025 |
| Richard Paulson | (Principal Executive Officer) | |
| /s/ Lori Macomber Lori Macomber | Executive Vice President, Chief Financial Officer and Treasurer | February 19, 2025 |
| (Principal Financial Officer) | ||
| /s/ Kristin Abate | Vice President, Chief Accounting Officer and Assistant Treasurer | February 19, 2025 |
| Kristin Abate | (Principal Accounting Officer) | |
| /s/ Garen G. Bohlin | Director | February 19, 2025 |
| Garen G. Bohlin | ||
| /s/ Barry E. Greene | Director | February 19, 2025 |
| Barry E. Greene | ||
| /s/ Mansoor Raza Mirza | Director | February 19, 2025 |
| Mansoor Raza Mirza, M.D. | ||
| /s/ Christy J. Oliger | Director | February 19, 2025 |
| Christy J. Oliger | ||
| /s/ Deepika R. Pakianathan | Director | February 19, 2025 |
| Deepika R. Pakianathan, Ph.D. | ||
| /s/ Chen Schor | Director | February 19, 2025 |
| Chen Schor | ||
| /s/ Zhen Su | Director | February 19, 2025 |
| Zhen Su, M.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.